Items Tagged ‘Paraganglioma’

August 12th, 2015

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma


The U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra is currently being evaluated in a pivotal Phase 2b trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received Orphan Drug and […]

View full entry

Tags: azedra, General, News, Other News Topics (not Types of Cancer), Paraganglioma, Pheochromocytoma